San Francisco, CA (March 6, 2019) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided updates on its programs. For the fourth quarter 2018, KindredBio reported net product revenues of $1.3 […]
Wednesday, March 6, 2019 Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID: 6089328 For more information about this event, please see the press release.
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019 San Francisco, CA (February 19, 2019) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth […]
Monday, February 25, 2019 Location: Bank of America Tower, One Bryant Park, 51st Floor, NY Presentation time: 9:25 – 10:05 AM ET Company Attendee: Richard Chin, CEO Webcast URL: Click here For more information about this event, please see the press release.
Tuesday, March 12, 2019 Location: Loews Miami Beach Hotel, Miami Beach, FL Presentation time: 2:05 – 2:30 PM ET Company Attendee: Denise Bevers, President and COO Webcast URL: Click here For more information about this event, please see the press release.
SAN FRANCISCO, February 13, 2019 — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York City and at the Barclays Global Healthcare Conference on March 12 in Miami. During this […]
SAN FRANCISCO, California. (January 23, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional […]
San Francisco, CA. (January 22, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication. In announcing the honor, Animal Pharm noted KindredBio’s transition to a […]
SAN FRANCISCO, California. (January 18, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount […]
SAN FRANCISCO, California. (January 17, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. All of the common stock is being offered by KindredBio. In addition, KindredBio intends to grant the underwriters a […]
0.00 (0.00%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
